Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jul 27, 2013 in Breast cancer | 2 comments

In a nutshell

This review analyzed a number of studies investigating the occurrence of joint pain (arthralgia) as a side effect caused by aromatase inhibitors (AI's) in patients with estrogen receptor-positive (ER+) breast cancer.

Some background

Aromatase is an enzyme that facilitates the production of the hormone estrogen. Estrogen promotes growth of cancer cells in ER+ breast cancer. AI's are a class of drugs that work by blocking the action of the enzyme aromatase, thus inhibiting estrogen production. This means that less estrogen is available to stimulate the growth of cancer cells. Examples of AI's include letrozole (femara), exemestane (aromasin), anastrozole (arimidex), and vorozole (rivizor).

Although AI's have been proven to improve survival of ER+ breast cancer patients, they have been associated with several side effects due to the reduced levels of estrogen hormone. Possible side effects of AI treatment include arthralgia (joint pain), arthritis (joint inflammation) and osteoporosis (reduction in the density of the bones making them prone to fractures). These side effects may increase the rate of treatment non-compliance (failure to complete treatment) in patients.

Methods & findings

A number of studies involving AI use were analyzed in this review. All studies confirmed improved survival rates in patients using AI's.

One study involving 200 women showed that 47% of AI users developed AI related arthralgia. Another study reviewed here compared the occurrence of arthralgia between three types of AI's: exemestane, anastrazole, and letrozole. No difference in the rate of arthralgia was noted between these patients.

In relation to treatment non-compliance, several studies showed that between 13% to 22% of patients discontinued AI treatment due to arthralgia.

The bottom line

In summary, although AI's improve survival rate in patients with ER+ breast cancer, a large number of patients fail to follow treatment due to arthralgia.

What’s next?

Consult with your physician on how to reduce AI related side effects.

Published By :

Annals of oncology

Date :

May 31, 2013

Original Title :

Aromatase inhibitor-induced arthralgia: a review.

click here to get personalized updates